Patient characteristics
Characteristic . | Nonablative; n = 73 . | Ablative; n = 73 . | P . |
|---|---|---|---|
| Median age, y | 54 | 48 | < 10-4 |
| Range, y | 21-72 | 21-63 | |
| Age group, % | .35 | ||
| Younger than 20 y | 0 | 0 | |
| 20-40 y | 12 | 18 | |
| Older than 40 y | 88 | 82 | |
| Sex, M/F, % | 64/36 | 60/40 | .61 |
| Diagnosis, % | .005 | ||
| MM | 26 | 16 | |
| MDS | 18 | 12 | |
| NHL | 15 | 18 | |
| CLL | 12 | 10 | |
| HD | 10 | 1 | |
| AML | 8 | 30 | |
| CML | 7 | 7 | |
| Waldenstrom | 3 | 0 | |
| ALL | 1 | 5 | |
| Time to transplantation, mo (range) | 22 (2-159) | 12 (1-198) | .002 |
| Previous failed auto, % | 16 | 0 | < 10-4 |
| Previous planned auto, % | 21 | 0 | < 10-4 |
| Disease status, %* | .60 | ||
| Low risk | 10 | 12 | |
| High risk | 90 | 88 | |
| Hematopoietic cell source, % | < 10-4 | ||
| Marrow | 0 | 30 | |
| G-PBMC | 100 | 70 | |
| CMV risk group, %† | .62 | ||
| High risk | 52 | 48 | |
| Low/intermediate risk | 48 | 52 | |
| Conditioning regimen, % | — | ||
| TBI (2 Gy) | 55 | — | |
| Fludarabine + TBI (2 Gy) | 45 | — | |
| Cy + TBI (12-13.5 Gy) | — | 48 | |
| Bu(t) + Cy‡ | — | 25 | |
| Bu(t) + TMI (9 Gy) ± Cy | — | 16 | |
| Bu + TBI | — | 11 | |
| GVHD prophylaxis, % | — | ||
| CSP + MMF | 100 | 7 | |
| CSP + MTX | — | 92 | |
| CSP + TMTX | — | 1 |
Characteristic . | Nonablative; n = 73 . | Ablative; n = 73 . | P . |
|---|---|---|---|
| Median age, y | 54 | 48 | < 10-4 |
| Range, y | 21-72 | 21-63 | |
| Age group, % | .35 | ||
| Younger than 20 y | 0 | 0 | |
| 20-40 y | 12 | 18 | |
| Older than 40 y | 88 | 82 | |
| Sex, M/F, % | 64/36 | 60/40 | .61 |
| Diagnosis, % | .005 | ||
| MM | 26 | 16 | |
| MDS | 18 | 12 | |
| NHL | 15 | 18 | |
| CLL | 12 | 10 | |
| HD | 10 | 1 | |
| AML | 8 | 30 | |
| CML | 7 | 7 | |
| Waldenstrom | 3 | 0 | |
| ALL | 1 | 5 | |
| Time to transplantation, mo (range) | 22 (2-159) | 12 (1-198) | .002 |
| Previous failed auto, % | 16 | 0 | < 10-4 |
| Previous planned auto, % | 21 | 0 | < 10-4 |
| Disease status, %* | .60 | ||
| Low risk | 10 | 12 | |
| High risk | 90 | 88 | |
| Hematopoietic cell source, % | < 10-4 | ||
| Marrow | 0 | 30 | |
| G-PBMC | 100 | 70 | |
| CMV risk group, %† | .62 | ||
| High risk | 52 | 48 | |
| Low/intermediate risk | 48 | 52 | |
| Conditioning regimen, % | — | ||
| TBI (2 Gy) | 55 | — | |
| Fludarabine + TBI (2 Gy) | 45 | — | |
| Cy + TBI (12-13.5 Gy) | — | 48 | |
| Bu(t) + Cy‡ | — | 25 | |
| Bu(t) + TMI (9 Gy) ± Cy | — | 16 | |
| Bu + TBI | — | 11 | |
| GVHD prophylaxis, % | — | ||
| CSP + MMF | 100 | 7 | |
| CSP + MTX | — | 92 | |
| CSP + TMTX | — | 1 |
MM indicates multiple myeloma; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphocytic leukemia; G-PBMC, granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells; CMV, cytomegalovirus; —, not applicable; TBI, total body irradiation; Cy, cyclophosphamide; Bu(t), busulfan (targeted); TMI, total marrow irradiation (modified TBI); GVHD, graft-versus-host disease; CSP, cyclosporine; MMF, mycophenolate mofetil, MTX, methotrexate; TMTX, trimetrexate.
Low risk disease includes CML in first chronic phase; AML or ALL in first complete remission; early MDS (refractory anemia or refractory anemia with ringed sideroblasts); or agnogenic myeloid metaplasia/myelofibrosis without prior treatment. High-risk disease includes all other classifications
High-risk CMV indicates patient CMV+; Low/intermediate risk, patient- and the donor- or+21
One patient received 16 mg/kg Bu